143 related articles for article (PubMed ID: 26758533)
1. Anticancer Potential and Molecular Targets of Pristimerin: A Mini- Review.
Yousef BA; Hassan HM; Zhang LY; Jiang ZZ
Curr Cancer Drug Targets; 2017; 17(2):100-108. PubMed ID: 26758533
[TBL] [Abstract][Full Text] [Related]
2. Pristimerin exhibits in vitro and in vivo anticancer activities through inhibition of nuclear factor-кB signaling pathway in colorectal cancer cells.
Yousef BA; Hassan HM; Zhang LY; Jiang ZZ
Phytomedicine; 2018 Feb; 40():140-147. PubMed ID: 29496166
[TBL] [Abstract][Full Text] [Related]
3. Pristimerin demonstrates anticancer potential in colorectal cancer cells by inducing G1 phase arrest and apoptosis and suppressing various pro-survival signaling proteins.
Yousef BA; Guerram M; Hassan HM; Hamdi AM; Zhang LY; Jiang ZZ
Oncol Rep; 2016 Feb; 35(2):1091-100. PubMed ID: 26718323
[TBL] [Abstract][Full Text] [Related]
4. Anticancer activity of pristimerin in epidermal growth factor receptor 2-positive SKBR3 human breast cancer cells.
Lee JS; Yoon IS; Lee MS; Cha EY; Thuong PT; Diep TT; Kim JR
Biol Pharm Bull; 2013; 36(2):316-25. PubMed ID: 23370361
[TBL] [Abstract][Full Text] [Related]
5. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.
Tiedemann RE; Schmidt J; Keats JJ; Shi CX; Zhu YX; Palmer SE; Mao X; Schimmer AD; Stewart AK
Blood; 2009 Apr; 113(17):4027-37. PubMed ID: 19096011
[TBL] [Abstract][Full Text] [Related]
6. Pristimerin inhibits breast cancer cell migration by up- regulating regulator of G protein signaling 4 expression.
Mu XM; Shi W; Sun LX; Li H; Wang YR; Jiang ZZ; Zhang LY
Asian Pac J Cancer Prev; 2012; 13(4):1097-104. PubMed ID: 22799288
[TBL] [Abstract][Full Text] [Related]
7. Pristimerin inhibits proliferation, migration and invasion, and induces apoptosis in HCT-116 colorectal cancer cells.
Yousef BA; Hassan HM; Guerram M; Hamdi AM; Wang B; Zhang LY; Jiang ZZ
Biomed Pharmacother; 2016 Apr; 79():112-9. PubMed ID: 27044819
[TBL] [Abstract][Full Text] [Related]
8. Pristimerin, a naturally occurring triterpenoid, attenuates tumorigenesis in experimental colitis-associated colon cancer.
Park JH; Kim JK
Phytomedicine; 2018 Mar; 42():164-171. PubMed ID: 29655682
[TBL] [Abstract][Full Text] [Related]
9. Pristimerin, a natural anti-tumor triterpenoid, inhibits LPS-induced TNF-α and IL-8 production through down-regulation of ROS-related classical NF-κB pathway in THP-1 cells.
Hui B; Yao X; Zhou Q; Wu Z; Sheng P; Zhang L
Int Immunopharmacol; 2014 Aug; 21(2):501-8. PubMed ID: 24957686
[TBL] [Abstract][Full Text] [Related]
10. Pristimerin Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive Review.
Sun J; Tian Z; Wu J; Li J; Wang Q; Huang S; Wang M
Drug Des Devel Ther; 2024; 18():1673-1694. PubMed ID: 38779590
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative activity of pristimerin isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells.
Costa PM; Ferreira PM; Bolzani Vda S; Furlan M; de Freitas Formenton Macedo Dos Santos VA; Corsino J; de Moraes MO; Costa-Lotufo LV; Montenegro RC; Pessoa C
Toxicol In Vitro; 2008 Jun; 22(4):854-63. PubMed ID: 18296021
[TBL] [Abstract][Full Text] [Related]
12. Pristimerin targeting NF-κB pathway inhibits proliferation, migration, and invasion in esophageal squamous cell carcinoma cells.
Tu Y; Tan F; Zhou J; Pan J
Cell Biochem Funct; 2018 Jun; 36(4):228-240. PubMed ID: 29781107
[TBL] [Abstract][Full Text] [Related]
13. Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells.
Yang H; Landis-Piwowar KR; Lu D; Yuan P; Li L; Reddy GP; Yuan X; Dou QP
J Cell Biochem; 2008 Jan; 103(1):234-44. PubMed ID: 17541980
[TBL] [Abstract][Full Text] [Related]
14. Pristimerin Induces Autophagy-Mediated Cell Death in K562 Cells through the ROS/JNK Signaling Pathway.
Liu Y; Ren Z; Li X; Zhong J; Bi Y; Li R; Zhao Q; Yu X
Chem Biodivers; 2019 Aug; 16(8):e1900325. PubMed ID: 31290253
[TBL] [Abstract][Full Text] [Related]
15. Anticancer activity of pristimerin in ovarian carcinoma cells is mediated through the inhibition of prosurvival Akt/NF-κB/mTOR signaling.
Gao X; Liu Y; Deeb D; Arbab AS; Gautam SC
J Exp Ther Oncol; 2014; 10(4):275-83. PubMed ID: 25509983
[TBL] [Abstract][Full Text] [Related]
16. Triterpenoids as new promising anticancer drugs.
Petronelli A; Pannitteri G; Testa U
Anticancer Drugs; 2009 Nov; 20(10):880-92. PubMed ID: 19745720
[TBL] [Abstract][Full Text] [Related]
17. Pristimerin effectively inhibits the malignant phenotypes of uveal melanoma cells by targeting NF‑κB pathway.
Zhang B; Zhang J; Pan J
Int J Oncol; 2017 Sep; 51(3):887-898. PubMed ID: 28766683
[TBL] [Abstract][Full Text] [Related]
18. Triterpenoid pristimerin induced HepG2 cells apoptosis through ROS-mediated mitochondrial dysfunction.
Guo Y; Zhang W; Yan YY; Ma CG; Wang X; Wang C; Zhao JL
J BUON; 2013; 18(2):477-85. PubMed ID: 23818365
[TBL] [Abstract][Full Text] [Related]
19. Isolation, Characterization and Anticancer Potential of Cytotoxic Triterpenes from Betula utilis Bark.
Mishra T; Arya RK; Meena S; Joshi P; Pal M; Meena B; Upreti DK; Rana TS; Datta D
PLoS One; 2016; 11(7):e0159430. PubMed ID: 27453990
[TBL] [Abstract][Full Text] [Related]
20. Pristimerin Inhibits LPS-Triggered Neurotoxicity in BV-2 Microglia Cells Through Modulating IRAK1/TRAF6/TAK1-Mediated NF-κB and AP-1 Signaling Pathways In Vitro.
Hui B; Zhang L; Zhou Q; Hui L
Neurotox Res; 2018 Feb; 33(2):268-283. PubMed ID: 29119451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
